Patents by Inventor Sangeeta Hanurmesh Rivankar
Sangeeta Hanurmesh Rivankar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220203042Abstract: A safety housing based implant/medicament injecting system. System includes a needle assembly prefilled implant/medicament for injection and an injecting needle/cannula, a housing for accommodating the needle assembly under usual bias inside said housing, a plunger means having a plunger rod configured for stage wise forward motion including an initial injecting plunger forward motion with the needle assembly within the housing to first engage the needle assembly with the housing and subsequent continuing injecting plunger forward motion independent of the needle assembly for injecting of the implant/medicament, and post injecting return of the needle assembly secured inside said housing blocking any subsequent use thereof.Type: ApplicationFiled: January 25, 2022Publication date: June 30, 2022Applicant: BHARAT SERUMS AND VACCINES LTDInventors: Gautam Vinod DAFTARY, Suresh Kumar NATARAJAN, Vasanthan MANI, Cyril Fernandez Lourdnathan JOSEPH, Sangeeta Hanurmesh RIVANKAR
-
Publication number: 20220143321Abstract: A safety housing based implant/medicament injecting system. System includes a needle assembly prefilled implant/medicament for injection and an injecting needle/cannula, a housing for accommodating the needle assembly under usual bias inside said housing, a plunger means having a plunger rod configured for stage wise forward motion including an initial injecting plunger forward motion with the needle assembly within the housing to first engage the needle assembly with the housing and subsequent continuing injecting plunger forward motion independent of the needle assembly for injecting of the implant/medicament, and post injecting return of the needle assembly secured inside said housing blocking any subsequent use thereof.Type: ApplicationFiled: January 25, 2022Publication date: May 12, 2022Applicant: BHARAT SERUMS AND VACCINES LTDInventors: Gautam Vinod DAFTARY, Suresh Kumar NATARAJAN, Vasanthan MANI, Cyril Fernandez Lourdnathan JOSEPH, Sangeeta Hanurmesh RIVANKAR
-
Publication number: 20220143326Abstract: A safety housing based implant/medicament injecting system. System includes a needle assembly prefilled implant/medicament for injection and an injecting needle/cannula, a housing for accommodating the needle assembly under usual bias inside said housing, a plunger means having a plunger rod configured for stage wise forward motion including an initial injecting plunger forward motion with the needle assembly within the housing to first engage the needle assembly with the housing and subsequent continuing injecting plunger forward motion independent of the needle assembly for injecting of the implant/medicament, and post injecting return of the needle assembly secured inside said housing blocking any subsequent use thereof.Type: ApplicationFiled: January 25, 2022Publication date: May 12, 2022Applicant: BHARAT SERUMS AND VACCINES LTDInventors: Gautam Vinod DAFTARY, Suresh Kumar NATARAJAN, Vasanthan MANI, Cyril Fernandez Lourdnathan JOSEPH, Sangeeta Hanurmesh RIVANKAR
-
Patent number: 11273266Abstract: A safety housing based implant/medicament injecting system. System includes a needle assembly prefilled implant/medicament for injection and an injecting needle/cannula, a housing for accommodating the needle assembly under usual bias inside said housing, a plunger means having a plunger rod configured for stage wise forward motion including an initial injecting plunger forward motion with the needle assembly within the housing to first engage the needle assembly with the housing and subsequent continuing injecting plunger forward motion independent of the needle assembly for injecting of the implant/medicament, and post injecting return of the needle assembly secured inside said housing blocking any subsequent use thereof.Type: GrantFiled: October 3, 2016Date of Patent: March 15, 2022Assignee: BHARAT SERUMS AND VACCINES LTDInventors: Gautam Vinod Daftary, Suresh Kumar Natarajan, Vasanthan Mani, Cyril Fernandez Lourdnathan Joseph, Sangeeta Hanurmesh Rivankar
-
Publication number: 20190175844Abstract: A safety housing based implant/medicament injecting system. System includes a needle assembly prefilled implant/medicament for injection and an injecting needle/cannula, a housing for accommodating the needle assembly under usual bias inside said housing, a plunger means having a plunger rod configured for stage wise forward motion including an initial injecting plunger forward motion with the needle assembly within the housing to first engage the needle assembly with the housing and subsequent continuing injecting plunger forward motion independent of the needle assembly for injecting of the implant/medicament, and post injecting return of the needle assembly secured inside said housing blocking any subsequent use thereof.Type: ApplicationFiled: October 3, 2016Publication date: June 13, 2019Applicant: BHARAT SERUMS AND VACCINES LTD.Inventors: Gautam Vinod DAFTARY, Suresh Kumar NATARAJAN, Vasanthan MANI, Cyril Fernandez Lourdnathan JOSEPH, Sangeeta Hanurmesh RIVANKAR
-
Patent number: 9005655Abstract: The present invention provides a long circulating non-pegylated liposomal doxorubicin hydrochloride composition for parenteral administration and a process for its preparation. The circulation time in Swiss albino mice is at least 25 times longer than conventional non-liposomal formulations. The non-pegylated liposomes are stable, exhibit low toxicity and have been found to be efficacious in different tumor models.Type: GrantFiled: July 17, 2008Date of Patent: April 14, 2015Assignee: Bharat Serums & Vaccines Ltd.Inventors: Gautam Vinod Daftary, Srikanth Annappa Pai, Sangeeta Hanurmesh Rivankar
-
Patent number: 8980310Abstract: The present invention provides a long circulating non-pegylated liposomal doxorubicin hydrochloride composition for parenteral administration and a process for its preparation. The circulation time in Swiss albino mice is at least 25 times longer than conventional non-liposomal formulations. The non-pegylated liposomes are stable, exhibit low toxicity and have been found to be efficacious in different tumor models.Type: GrantFiled: December 31, 2003Date of Patent: March 17, 2015Assignee: Bharat Serums and Vaccines, Ltd.Inventors: Gautam Vinod Daftary, Srikanth Annappa Pai, Sangeeta Hanurmesh Rivankar
-
Patent number: 8759404Abstract: The invention discloses a stable intravenous Propofol oil-in-water emulsion composition having mixed preservatives of low toxicity that is capable of withstanding accidental contamination of bacteria and fungi. The preservative system employed comprising of monoglyceryl ester of lauric acid (Monolaurin) and a member selected from (a) capric acid and/or its soluble alkaline salts or its monoglyceryl ester (Monocaprin); (b) edetate; and (c) capric acid and/or its soluble alkaline salts or its monoglyceryl ester (Monocaprin) and edetate.Type: GrantFiled: March 2, 2007Date of Patent: June 24, 2014Assignee: Bharat Serums & Vaccines Ltd.Inventors: Gautam Vinod Daftary, Srikanth Annappa Pai, Girish Narasimha Shanbhag, Sangeeta Hanurmesh Rivankar
-
Publication number: 20080279927Abstract: The present invention provides a long circulating non-pegylated liposomal doxorubicin hydrochloride composition for parenteral administration and a process for its preparation. The circulation time in Swiss albino mice is at least 25 times longer than conventional non-liposomal formulations. The non-pegylated liposomes are stable, exhibit low toxicity and have been found to be efficacious in different tumor models.Type: ApplicationFiled: July 17, 2008Publication date: November 13, 2008Applicant: Bharat Serums & Vaccines LtdInventors: Gautam Vinod DAFTARY, Srikanth Annappa Pai, Sangeeta Hanurmesh Rivankar
-
Patent number: 7199111Abstract: The present invention provides aqueous Ifosfamide compositions and a process for their preparation, in which the compositions have a reduced toxicity over and above the concomitant use of the uroprotective agent, Mesna. Aqueous Ifosfamide compositions can be prepared at concentrations as high has 1,1000 mg/ml.Type: GrantFiled: December 2, 2003Date of Patent: April 3, 2007Assignee: Bharat Serums & Vaccines Ltd.Inventors: Gautam Vinod Daftary, Srikanth Annappa Pai, Sangeeta Hanurmesh Rivankar, Praveen Kumar Subbappa
-
Patent number: 7138387Abstract: Sterile pharmaceutical stable autoclaved clear aqueous compositions of propofol (2,6-Diisopropyl phenol) suitable for parenteral administration are described. The compositions essentially consist of a complex of propofol with 2-hydroxypropyl-?-cyclodextrin in a weight ratio of 1:30–1:60. This complex of propofol with 2-hydroxypropyl-?-cyclodextrin produces a clear aqueous composition that is stable to autoclaving. The composition is effective as an anaesthetic agent. The process of making these synergistic compositions has been described.Type: GrantFiled: December 14, 2000Date of Patent: November 21, 2006Assignee: Bharat Serums and Vaccines LimitedInventors: Srikanth Annappa Pai, Sangeeta Hanurmesh Rivankar, Shilpa Sudhakar Kocharekar
-
Patent number: 7053061Abstract: Parenteral compositions of oil-coated-Amphotericin B in structured-emulsion form, having LD50 of at least 400 mg/kg in mice and process for making the same have been described. The process essentially requires dispersing Amphotericin B in oily vehicle and dispersing emulsifier in the aqueous phase. The process of present invention is simple, cost effective and gives a stable product suitable for parenteral administration. Amphotericin B emulsion compositions prepared by the process of the present invention may be administered to human beings and animals for the treatment of fungal infections, with substantially equivalent or greater efficacy and low drug toxicity as compared to the conventional composition containing Amphotericin B and sodium desoxycholate.Type: GrantFiled: June 19, 2001Date of Patent: May 30, 2006Assignee: Bharat Serums and Vaccines LimitedInventors: Srikanth Annappa Pai, Sangeeta Hanurmesh Rivankar, Shilpa Sudhakar Kocharekar
-
Publication number: 20040235964Abstract: The present invention relates to a stable clear sterile aqueous composition of Propofol suitable for parenteral administration and a process for making the same. The composition comprises Propofol, TPGS and water. The composition of present invention gives clear product suitable for parenteral administration overcoming the disadvantages of emulsion formulation. The ratio of propofol to TPGS is at least 1:10 (by wt.) and the content of TPGS is from 1 to 20% w/v in the composition. The composition is rendered sterile by end autoclaving.Type: ApplicationFiled: February 20, 2004Publication date: November 25, 2004Inventors: Srikanth Annappa Pai, Sangeeta Hanurmesh Rivankar, Shilpa Sudhakar Kocharekar
-
Publication number: 20040186074Abstract: The present invention provides aqueous Ifosfamide compositions and a process for their preparation, in which the compositions have a reduced toxicity over and above the concomitant use of the uroprotective agent, Mesna. Aqueous Ifosfamide compositions can be prepared at concentrations as high has 1,1000 mg/ml.Type: ApplicationFiled: December 2, 2003Publication date: September 23, 2004Applicant: Bharats Serums & Vaccines LTd.Inventors: Gautam Vinod Daftary, Srikanth Annappa Pai, Sangeeta Hanurmesh Rivankar, Praveen Kumar Subbappa
-
Publication number: 20040137049Abstract: A low toxicity parenteral dimethyl sulfoxide free aqueous compositions containing Amphotericin B are described. The compositions essentially consist of in addition an Amphotericin B, phospholipids and sodium chloride. The compositions are sterilized by autoclaving. The process of making these compositions without the use of solvents for dissolving Amphotericin B have been described. The compositions are indicated for the treatment of invasive fungal infections.Type: ApplicationFiled: March 1, 2004Publication date: July 15, 2004Inventors: Srikanth Annappa Pai, Sangeeta Hanurmesh Rivankar
-
Publication number: 20040014718Abstract: Sterile pharmaceutical stable autoclaved clear aqueous compositions of propofol (2,6-Diisopropyl phenol) suitable for parenteral administration are described. The compositions essentially consist of a complex of propofol with 2-hydroxypropyl-&bgr;-cyclodextrin in a weight ratio of 1:30-1:60. This complex of propofol with 2-hydroxypropyl-&bgr;-cyclodextrin produces a clear aqueous composition that is stable to autoclaving. The composition is effective as an anaesthetic agent. The process of making these synergistic compositions has been described.Type: ApplicationFiled: August 18, 2003Publication date: January 22, 2004Inventors: Srikanth Annappa Pai, Sangeeta Hanurmesh Rivankar, Shilpa Sudhakar Kocharekar
-
Publication number: 20030206929Abstract: Parenteral compositions of oil-coated-Amphotericin B in structured-emulsion form, having LD50 of at least 400 mg/kg in mice and process for making the same have been described. The process essentially requires dispersing Amphotericin B in oily vehicle and dispersing emulsifier in the aqueous phase. The process of present invention is simple, cost effective and gives a stable product suitable for parenteral administration. Amphotericin B emulsion compositions prepared by the process of the present invention may be administered to human beings and animals for the treatment of fungal infections, with substantially equivalent or greater efficacy and low drug toxicity as compared to the conventional composition containing Amphotericin B and sodium desoxycholate.Type: ApplicationFiled: May 30, 2003Publication date: November 6, 2003Inventors: Srikanth Annappa Pai, Sangeeta Hanurmesh Rivankar, Shilpa Sudhakar Korcharekar
-
Patent number: 6572884Abstract: A sterile pharmaceutical cisplatin composition as an oil-in-water emulsion having low toxicity for parenteral administration comprising: a) an oily phase selected from the group consisting of: vegetable oils, esters of medium or long chain fatty acids, and fractionated or modified oils; b) cisplatin incorporated in the oily phase; c) an emulsifier selected from the group consisting of: natural phosphatides; modified phosphatides, and synthetic non-ionic surfactants; d) a tonicity modifying agent selected from the group of compounds consisting of: glycerin, mannitol, and dextrose; e) a chelating agent selected from the group of compounds consisting of: edetates, and desferrioxamine mesylate; and f) water.Type: GrantFiled: June 14, 2002Date of Patent: June 3, 2003Inventors: Srikanth Annappa Pai, Sangeeta Hanurmesh Rivankar, Shilpa Sudhakar Kocharekar